Long-term biocompatibility, chemistry, and function of microencapsulated pancreatic islets
Introduction
The recent advances in clinical islet transplantation [1] have increased the interest in transplantation of an endogenous insulin source for control of the diabetic blood sugar. A major obstacle to overcome the large-scale application is the requirement to apply effective immunosuppression, which is associated with serious side effects, especially when applied for a life-long period. Immunoisolation by microencapsulation does not require the use of immunosuppression and has therefore the potential to be developed into a widely applicable therapy for patients with insulin dependent diabetes.
A commonly used procedure for immunoprotection is microencapsulation of tissues in alginate-based capsules as originally described by Lim and Sun [2]. During recent years, important advances have been made with this technology. Human trials have been started and showed temporary but pertinent survival of human microencapsulated tissue after allotransplantation of encapsulated parathyroid cells [3] and islets [4]. Also, microencapsulation has been shown to allow for prolonged survival of xenotransplanted islet grafts in both chemically induced and autoimmune diabetic rodents [5], dogs [4], and monkeys [6]. Although this illustrates the principle applicability of the alginate-encapsulation technique, a fundamental barrier has to be overcome since graft survival varies considerably from several days to months [7]. This variation in success rate is usually attributed to differences in the biological responses (i.e. biocompatibility) against the applied capsules. In order to improve the capsule properties, many groups have introduced their own technical modifications. As a consequence there are many different procedures with specific chemical characteristics which, regretfully, are never documented.
In the foregoing years we have concentrated on the identification and deletion of factors inducing biological responses against encapsulated islets. Alginates are composed of mannuronic acid (M) and guluronic acid (G) and can be contaminated with inflammatory substances. We found that the biological response against capsules can be reduced by applying alginates with a G-content of 40–45% instead of more than 50% and by introducing alginates with a high purity degree [5], [8], [9], [10], [11]. Also, an inadequate mechanical integrity of the capsules [9], [12] can cause immunological reactions in the recipient. Finally, we found that grafts can fail as the consequence of incomplete encapsulation of islets [13], [14].
In the present study, we changed the capsule production process by applying modifications which have previously shown to influence the biological response against capsule grafts [5], [8], [9], [10], [11], [12]. Empty capsules produced according to our modified procedure were implanted in the peritoneal cavity and retrieved after varying time intervals for evaluation of the biological response against the capsules. Next, syngeneic and allogeneic rat islets were encapsulated and transplanted in diabetic rats in order to assess the immunoprotective properties of the capsules. Finally, we analyzed and present the chemical structure of the immunoprotective capsule, which remained free of any biological response up to 2 years after implantation in rats.
Section snippets
Design of the study
Only highly purified alginates were applied in order to exclude that contaminating components were the cause of an inflammatory response. Capsules were prepared of alginates with an intermediate guluronic acid (G) content (40% G) in order to prevent biological responses associated with a high G-content. High viscosity alginate solutions were applied to produce capsules with an adequate mechanical integrity. The capsules were inspected before and after implantation in order to confirm that the
Biological response against empty capsules
The vast majority of empty alginate-PLL capsules was freely floating in the peritoneal cavity without adhesion to the abdominal organs (Fig. 1A). The free capsules could readily be flushed out of the peritoneal cavity, resulting in an explantation of 80–100% up to 2 years postimplant (Table 1). Of the recovered capsules only a portion of not more than 10% of the capsules contained some macrophages and fibroblasts. This small percentage of overgrowth was caused by imperfections on the capsule
Discussion
Up to now the success rates of transplantation of microencapsulated islets were low [5], [24], [25], [26], [27]. This is mainly caused by insufficient biocompatibility of the applied capsule materials [5], [28], [29], [30] which induced a non-specific foreign body reaction against not only a small portion but against the whole capsule graft with fibrosis of the capsules and necrosis of the islets as a consequence. In the present study, we show for the first time that a procedure in which
References (35)
- et al.
Parathyroid allotransplantation without immunosuppression
Lancet
(1997) - et al.
Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane
Biochim Biophys Acta
(1984) - et al.
Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules
Biomaterials
(1997) A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal
Physiol Behav
(1969)- et al.
Upscaling the production of encapsulated islets
Biomaterials
(1997) - et al.
Alginate polycation microcapsules. I. Interaction between alginate and polycation
Biomaterials
(1996) - et al.
Biocompatibility of mannuronic acid-rich alginates
Biomaterials
(1997) - et al.
Alginate polycation microcapsules II. Some functional properties
Biomaterials
(1996) - et al.
Interaction of acid polysaccharides with polylysine enantiomers, conformation probe in solution
Carbohydr Polym
(1991) - et al.
Interaction of alginate and pectins with cationic polypeptides
Carbohydr Res
(1990)